Article
Advanced Medical Optics (AMO, Santa Ana, CA) redefined its position in the ophthalmic community when it reached a definitive agreement April 21 to acquire Pfizer’s surgical ophthalmology business for $450 million in cash. The deal will boost AMO’s revenue base by 25% and allow the company bragging rights to the Healon line of viscoelastic products, the CeeOn and Tecnis IOLs, and the Baerveldt glaucoma shunt.“You don’t see many of these deals come across in a lifetime-in any industry,” said AMO President and Chief Executive Officer James V. Mazzo
Study validates long-term efficacy of MicroPulse TLT for glaucoma management